Shopping Cart
- Remove All
- Your shopping cart is currently empty
Denifanstat (FASN-IN-2) is a fatty acid synthase (FASN) inhibitor (IC50=0.052 μM, EC50=0.072 μM) with selective and oral activity. Denifanstat has been used in studies of steatohepatitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $83 | In Stock | |
5 mg | $197 | In Stock | |
10 mg | $332 | In Stock | |
25 mg | $558 | In Stock | |
50 mg | $788 | In Stock | |
100 mg | $1,120 | In Stock | |
500 mg | $2,230 | In Stock | |
1 mL x 10 mM (in DMSO) | $228 | In Stock |
Description | Denifanstat (FASN-IN-2) is a fatty acid synthase (FASN) inhibitor (IC50=0.052 μM, EC50=0.072 μM) with selective and oral activity. Denifanstat has been used in studies of steatohepatitis. |
Targets&IC50 | FASN:0.052 μM |
In vitro | METHODS: MDA-MD-231 and MDA-MB-231-BR cells were treated with Denifanstat (1-10.3 µM) for 6-30 h. Cell migration was detected by wound healing assay. RESULTS: Cell migration was inhibited in MDA-MB-231-BR cells but not in parental MDA-MD-231 cells in a dose-dependent manner. [1] |
In vivo | METHODS: To assay antitumor activity in vivo, Denifanstat (100 mg/kg, 30% PEG400) was administered by gavage to SCID mice bearing PC-3M/HOXB13KD xenografts once daily for six weeks. RESULTS: Five weeks after inoculation, HOXB13-KD mice showed significant metastasis in IVIS, which was completely alleviated by Denifanstat treatment.Denifanstat treatment significantly prolonged metastasis-free survival in both control and HOXB13-KD mice. [2] |
Alias | TVB-2640, TVB2640, FASN-IN-2 |
Molecular Weight | 439.55 |
Formula | C27H29N5O |
Cas No. | 1399177-37-7 |
Smiles | Cc1n[nH]c(n1)-c1cc(C(=O)N2CCC(CC2)c2ccc(cc2)C#N)c(C)cc1C1CCC1 |
Relative Density. | 1.27 g/cm3 (Predicted) |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (136.5 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 6 mg/mL (13.65 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.